Featured Story | By Ben Adams Pharma’s reputation may have soared amid the pandemic, but that came with a brighter spotlight on DEI issues. In recent years, pharma has been trying to penetrate social issues of diversity, equity and inclusion more deeply into its corporate psyche. read more |
| |
|---|
|
Top Stories By Max Bayer As venture capital pours into budding biotechs, we're launching the Fierce Biotech Fundraising Tracker to keep tabs on all things financing. read more By Dave Muoio Executives from HCA Healthcare, Universal Health Services and Tenet Healthcare recounted early negotiating wins and favorable public comments from commercial payers as signs they'll be able to secure rate increases for the coming year. read more By Andrea Park The dream of a completely closed-loop system for diabetes management is now closer than ever for many Type 1 diabetes patients, thanks to the widespread U.S. launch of Insulet's completely automated, continuous glucose monitor-compatible insulin delivery device. read more By Eric Sagonowsky After years of government standstill on drug prices in the U.S., could the Senate this week pass a "watershed" bill enabling drug price negotiations? It remains to be seen, but analysts are busy poring over the available details to see how the legislation may affect the industry's top players. read more By Heather Landi An Oracle executive vowed to get the Veterans Affairs' troubled health IT project "back on track" as House lawmakers warned they would consider scuttling the multi-billion-dollar project unless officials show progress in the coming months. read more By James Waldron Neurodegeneration is one of the hottest areas of drug development at the moment. For Johnson & Johnson’s R&D arm Janssen, this involves a two-pronged strategy of precision medicines for diseases like Alzheimer’s while at the same time working on biomarkers that can identify patients who will benefit most. read more By Andrea Park About a month and a half after pausing shipments of its Tablo hemodialysis system for at-home use, Outset Medical has secured the renewed FDA clearance it was waiting for, greenlighting new sales of the updated system. read more By Zoey Becker In the latest move in the long-running dispute over botched COVID-19 vaccine manufacturing, Johnson & Johnson revealed that it filed an arbitration demand against former manufacturing partner Emergent BioSolutions back in June. read more By Max Bayer Kazia Therapeutics has been dropped from a global adaptive clinical trial to find new treatments for an aggressive form of brain cancer. The company said it did not meet "pre-specified criteria" to advance in the trial, which the trial record defines as a specific efficacy threshold. read more By Conor Hale After dipping its toes in the healthcare space, the speaker maker Bose has found the water too cold. Bose announced that it has partnered with Lexie Hearing to outfit the latter's product lines with its technology, which was designed to allow wearers to program and control their hearing aids themselves without needing to visit the doctor. read more By Fraiser Kansteiner Gilead Sciences' triple-threat Biktarvy is already a standout in the HIV treatment space—and it’s the company's top seller, to boot. Now, Gilead is trumpeting data that could pave the way to millions of additional patients worldwide. read more By Annalee Armstrong Stealth BioTherapeutics has officially been handed its cloaking device thanks to a merger agreement signed with Morningside Venture (I) Investments that will take the mitochondrial dysfunction biotech private once again. read more By Conor Hale New data shows that six months’ use of Cognito Therapeutics' digital therapeutic could potentially reduce the rate of atrophy within the white matter of the brain. The company said it plans to launch new, pivotal trials this year in Alzheimer’s disease. read more By Annalee Armstrong Each year at Fierce, we spotlight women who are leading the way in the life sciences, from industry professionals and academics to venture capitalists and regulatory officials. read more By Paige Minemyer We are seeking leaders from across the industry who have made a measurable impact in healthcare over the past year, and who have proven that they are paving a new path forward for men and women both in the industry. read more Resources Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 
